Recursion Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75629V1044

SecurityRXRX / Recursion Pharmaceuticals, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership1,469,262 shares
Latest Disclosed Value $ 6,009,282
Barclays Plc ownership in RXRX / Recursion Pharmaceuticals, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 1,469,262 shares of Recursion Pharmaceuticals, Inc. (US:RXRX) valued at $6,009,282 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 1,550,226 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of -5.22% during the quarter. The current value of the position is $5,098,339 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (RXRX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

RXRX / Recursion Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 1,469,262 -80,964 -5.22 6,009 -20.57 0.0014
2026-03-31 2025-09-30 13F/A-3 RECURSION PHARMACEUTICALS IN COM 75629V104 1,550,226 385,537 33.10 7,565 28.37 0.0016
2026-03-19 2025-09-30 13F/A-2 RECURSION PHARMACEUTICALS IN COM 75629V104 697,432 -467,257 4,596 0.0012
2025-11-12 2025-09-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 1,550,226 385,537 7,565 0.0016
2026-02-27 2025-06-30 13F/A-2 RECURSION PHARMACEUTICALS IN COM 75629V104 1,164,689 573,683 97.07 5,893 88.52 0.0014
2025-08-14 2025-06-30 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 1,164,689 573,683 6 0.0014
2025-08-13 2025-06-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 1,164,689 573,683 6 0.0004
2026-03-17 2025-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 591,006 -42,119 -6.65 3,126 -26.95 0.0009
2025-05-15 2025-03-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 591,006 -42,119 3 0.0009
2026-03-19 2024-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 633,125 -64,307 -9.22 4,280 -6.90 0.0012
2025-02-13 2024-12-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 633,125 -64,307 4 0.0012
2026-03-31 2024-09-30 13F/A-2 RECURSION PHARMACEUTICALS IN COM 75629V104 697,432 304,278 77.39 4,596 55.90 0.0012
2024-11-19 2024-09-30 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 697,432 304,278 5 0.0012
2024-11-15 2024-09-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 697,432 304,278 5 0.0004
2026-03-23 2024-06-30 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 393,154 78,853 25.09 2,949 -5.90 0.0009
2024-08-14 2024-06-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 393,154 78,853 3 0.0009
2026-03-24 2024-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 314,301 -282,257 -47.31 3,134 -46.74 0.0011
2024-05-15 2024-03-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 314,301 -282,257 3 0.0011
2026-03-25 2023-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 596,558 38,787 6.95 5,882 37.88 0.0022
2024-02-15 2023-12-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 596,558 38,787 6 0.0022
2026-03-26 2023-09-30 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 557,771 369,103 195.64 4,267 202.77 0.0027
2023-11-07 2023-09-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 557,771 369,103 4 0.0027
2026-03-30 2023-06-30 13F/A-2 RECURSION PHARMACEUTICALS IN COM 75629V104 188,668 446 0.24 1,409 12.27 0.0009
2023-09-20 2023-06-30 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 188,668 446 1 0.0009
2023-08-03 2023-06-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 188,668 446 1 0.0009
2026-03-30 2023-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 188,222 -108,378 -36.54 1,255 -45.10 0.0006
2023-05-04 2023-03-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 188,222 -108,378 1 0.0006
2026-03-30 2022-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN COM 75629V104 296,600 184,366 164.27 2,287 91.30 0.0010
2023-02-13 2022-12-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 296,600 184,366 2 0.0010
2022-11-03 2022-09-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 112,234 91,762 448.23 1,195 619.88 0.0013
2022-08-12 2022-06-30 13F RECURSION PHARMACEUTICALS IN COM 75629V104 20,472 -2,556 -11.10 166 0.61 0.0001
2022-05-16 2022-03-31 13F RECURSION PHARMACEUTICALS IN COM 75629V104 23,028 23,028 165 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-11-19 2024-09-30 13F/A RECURSION PHARMACEUTICALS IN OPT Call 0 0 n/a n/a n/a
2026-03-31 2024-09-30 13F/A RECURSION PHARMACEUTICALS IN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-15 2024-09-30 13F RECURSION PHARMACEUTICALS IN OPT Call 0 0 n/a n/a n/a
2026-03-23 2024-06-30 13F/A RECURSION PHARMACEUTICALS IN OPT Call 60,000 450 n/a n/a n/a
2024-08-14 2024-06-30 13F RECURSION PHARMACEUTICALS IN OPT Call 60,000 0 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.